Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
This is an additional approval for Jyseleca, an oral, once-daily, JAK1 preferential inhibitor, for adult patients with moderately to severely active UC who have had an inadequate response or were intolerant to conventional therapies. The European Commission based its approval on data from the Phase IIb/III SELECTION program, which evaluated Jyseleca as an induction and maintenance therapy in the patient population now included in the label. Data from the SELECTION trial was published in The Lancet.
We are very pleased that the European Commission has approved Jyseleca as a treatment for people with UC. This decision further supports the efficacy and safety profile of Jyseleca, which was studied in over 1,250 UC patients. Our focus now is on making this treatment available as rapidly as possible to physicians and UC patients across the European Union, Onno van de Stolpe, chief executive officer of Galapagos said in a statement.
Ulcerative colitis is characterized by inflammation of the mucosal lining of the colon and rectum. There are more than two million people across Europe who are affected by ulcerative colitis.
Elsewhere around the globe:
Tokyo Institute of Technology Researchers at the Tokyo Institute of Technology have uncovered a novel role of nascent protein chains in stabilizing translating ribosomes. They suggest that longer peptide sequences spanning the ribosomal exit tunnel and bulky amino acid residues in the tunnel entry help stabilize the ribosome by bridging its subunits, ensuring uninterrupted translation. The findings indicate an intrinsic regulatory mechanism wherein the nascent peptide in collaboration with the ribosomal tunnel helps maintain ribosomal stability and continuity in translation elongation.
Cellenion Frances Cellenion, a BICO company, formerly known as CELLINK, forged an agreement with Thermo Fisher Scientific to advance single cell proteomics analyses. The goal of the partnership is to combine Cellenions cellenONE and proteoCHIPwith Thermo Fishers TMT multiplexing technologies and Thermo ScientificOrbitrapmass spectrometers to deliver complete solutions, from single cell isolation and automated sample preparation through to mass spectrometry (MS)-based proteomics analysis on single cells.
Pierre Fabre Also based in France, Pierre Fabre and Switzerlands EspeRare Foundation partnered to initiate the EDELIFE study assessing ER004, a prenatal treatment forXLHED(X-linkedHypohidroticEctodermal Dysplasia), a rareanddebilitating congenital disease.If positive,the studycould lead tothe first approved treatment for XLHED by 2026, the companies said in the announcement. XLHED is arare disease whichaffectsapproximately four of every 100,000 male births every year.This genetic disorderis adermatologic-relatedconditionthatleads toabnormal development of the skin,sweat glands,sebaceous glands, hair, oral cavity and respiratory mucosal glandsresultingin seriousclinical manifestationssuch ashyperthermia, craniofacial anomalies and recurrent respiratory infections. ER004 received Breakthrough Therapy designation from the U.S. Food and Drug Administration in 2020.
Cytovation AS Norway-based Cytovation AS has dosed its first patients in the Phase I/IIa CICILIA clinical trial assessing CyPep-1 in combination with Mercks Keytruda in patients with solid tumors.
CARMAT Artificial heart company CARMAT, which is based in France, announced the first implant of the Aeson artificial heart in The Netherlands. The implant procedure was performed bytheHeart Teamat the University Medical Center in Utrecht, The Netherlands.
LabCorp Labcorp opened a new, integrated bioanalytical laboratory in Singapore. The laboratory features new capabilities that enhance the substantial array of bioanalytical services, which will allow the company to meet increased demand from pharmaceutical and biotechnology companies.
Entos Pharmaceuticals Canada-based Entos and BioMarin Pharmaceutical entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline. Entos will apply the Fusogenix platform to formulate BioMarin product candidates aimed at the treatment of genetic diseases. Entos most advanced clinical program is Covigenix VAX-001, a COVID-19 DNA vaccine thatis the subject of an ongoing Phase II clinical trial in South Africa.
SOTIO Biotech Czech Republic-based SOTIO entered into a target-specific license and option agreement with LegoChem Biosciences Inc. to deploy that companys ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens. The deal enables SOTIO to combine its proprietary antibodies with LCBs ADC technology platform in order to deliver novel therapeutics for the treatment of solid tumors and includes LCBs proprietary conjugation technology ConjuAll and potent linker-payload platform including multiple different payloads.
Affibody AB Swedens Affibody forged an agreement with Acelyrin, Inc. to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases. Izokibep is a unique, antibody mimetic, IL-17A inhibitor designed to overcome the limitations of monoclonal antibodies. Affibody will receive $25 million in an upfront payment and the deal could swell to as much as $280 million when regulatory milestones are included.
CRISPR Therapeutics With an office inSwitzerland, CRISPR Therapeutics and ViaCyte, Inc. announced that Health Canada has approved the companies Clinical Trial Application for VCTX210, an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). Patient enrollment is expected to begin by the end of 2021. The Phase 1 trial of VCTX210 is designed to assess its safety, tolerability, and immune evasion in patients with T1D.
OncoOne Austrias OncoOne and GenScript ProBio entered into an agreement for thecell line development, drug substance and drug product manufacturingof therapeutic and diagnostic monoclonal antibodies (mAbs) directed against the promising immuno-oncology target, oxidized macrophage migration inhibitory factor (oxMIF). The companies will combine their respective expertise in drug discovery and manufacturing to bring the resulting mAb candidates into the clinic. Further terms of the agreement have not been disclosed.
GenSight Biologics Based in France, GenSight reported that a second patient with late-stage retinitis pigmentosa (RP) partially recovered visual function after treatment with GS030 optogenetic therapy. The GS030 optogenetic treatment, which combines gene therapy with the use of light-stimulating goggles, led to the patient being able to perceive and count objects one year after injection with GS030s gene therapy component. The patient is a participant in the ongoing PIONEER Phase I/II clinical trial of GS030. Data on a previous patient who exhibited a partial recovery was published earlier this year in Nature Medicine.
Saniona Denmarks Saniona initiated a Phase IIb study of Tesomet in patients withhypothalamic obesity (HO).Tesomet is an investigational fixed-dose combination therapy of tesofensine,a triple monoamine reuptake inhibitor, and metoprolol,a beta-1 selective blocker. Data from the trial are expected in thesecondhalf of 2023.
SofinnovaPartners European venture capital firm Sofinnova Partners has raised 150 million in capital for its early-stage environmental impact fund,bringing the firms total assets under management to 2.5 billion across its platform of investment strategies. Sofinnova Industrial Biotech II is part of the venture capital firms pioneering sustainability strategy initiated over a decade ago with the launch of the Sofinnova Green Seed Fund. The fund will continue to finance early-stage companiesharnessing biotechnology to develop sustainable solutions across the food, agriculture, chemical and materials sectors.
Go here to read the rest:
Global Roundup: Galapagos NV Wins European Approval for Ulcerative Colitis Therapy - BioSpace
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments